http://orcid.org/0000-0002-8322-475X
Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Laura Amanda Boos, Isla Leslie & James Larkin. (2020) Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs 29:7, pages 739-753.
Read now
Read now
Articles from other publishers (53)
Elena Carmona-RochaIvana Sullivan & Oriol Yélamos. (2023) Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response. Melanoma Research 33:6, pages 553-555.
Crossref
Crossref
S. S. Yargunin, I. V. Reshetov, Ya. N. Shoykhet, S. I. Samoylova, O. Yu. Chukhrai & S. N. Pyatakov. (2023) Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue. Innovative Medicine of Kuban:4, pages 42-50.
Crossref
Crossref
Rachel S. Goodman, Lorenza Di Guardo, Andrea Maurichi, Brendan Kirwin, Adnan Khattak, Vito Vanella, Joanna Lee, Aleigha Lawless, Juliane Czapla, Andrea Spagnoletti, Margherita Ambrosini, Elisabeth Livingstone, Georgina V. Long, Ryan J. Sullivan, Matteo S. Carlino, Victoria Atkinson, Claudia Trojanello, Paolo A. Ascierto, Dirk Schadendorf, Lydia Warburton, Alexander M. Menzies, Mario Santinami & Douglas B. Johnson. (2023) Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal of Cancer 194, pages 113354.
Crossref
Crossref
Nakul Dar, Sarah E. Gradecki & Elizabeth M. Gaughan. (2023) Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma. Frontiers in Oncology 13.
Crossref
Crossref
Mari Wilhelmsson, Foo Jen Chun, Rae S. M. Yeung, Fiona Krtizinger, Tara McKeown, Ailish Coblentz, Birgit Ertl‐Wagner, Uri Tabori, Ute Bartels & Anirban Das. (2023) Sarcoid‐like reaction in a child following prolonged therapeutic exposure to dabrafenib and trametinib for BRAF V600E mutated hypothalamic/chiasmatic glioma. Pediatric Blood & Cancer.
Crossref
Crossref
Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd & Bruce E. Johnson. (2023)
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
BRAF
V600
-Mutant Metastatic Non–Small-Cell Lung Cancer
. Journal of Clinical Oncology 41:21, pages 3700-3711.
Crossref
Crossref
Elisa A Rozeman, Judith M Versluis, Karolina Sikorska, Esmée P Hoefsmit, Petros Dimitriadis, Disha Rao, Ruben Lacroix, Lindsay G Grijpink-Ongering, Marta Lopez-Yurda, Birthe C Heeres, Bart A van de Wiel, Claudie Flohil, Aysegul Sari, Stijn W T P J Heijmink, Daan van den Broek, Annegien Broeks, Jan Willem B de Groot, Marieke A Vollebergh, Sofie Wilgenhof, Johannes V van Thienen, John B A G Haanen & Christian U Blank. (2023) IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation. Journal for ImmunoTherapy of Cancer 11:7, pages e006821.
Crossref
Crossref
Maximilian Haist, Henner Stege, Michael Kuske, Julia Bauer, Annika Klumpp, Stephan Grabbe & Matthias Bros. (2023) Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?. Cancer and Metastasis Reviews 42:2, pages 481-505.
Crossref
Crossref
Nausicaa Malissen & Jean-Jacques Grob. (2023) Treatment of Recurrent Melanoma Following Adjuvant Therapy. American Journal of Clinical Dermatology 24:3, pages 333-341.
Crossref
Crossref
Joanna Lee, Tasnia Ahmed, Andrea Maurichi, Lorenza Di Guardo, Anna M. Stagno, Lydia Warburton, Amelia. M. Taylor, Elisabeth Livingstone, Saba Rehman, Adnan Khattak, Katharina C. Kahler, Vito Vanella, Victoria Atkinson, Michael Millward, Dirk Schadendorf, Douglas B. Johnson, Paolo A. Ascierto, Axel Hauschild, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies & Matteo S. Carlino. (2023) BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. European Journal of Cancer 179, pages 87-97.
Crossref
Crossref
Paolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Natalia Zhukova, Jacob Schachter, Yibing Yan, Ivor Caro, Christian Hertig, Cloris Xue, Lieke Kusters, Grant A McArthur & Ralf Gutzmer. (2023) Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. The Lancet Oncology 24:1, pages 33-44.
Crossref
Crossref
Perrine Rousset, Stéphane Dalle, Laurent Mortier, Olivier Dereure, Sophie Dalac, Caroline Dutriaux, Marie-Thérèse Leccia, Delphine Legoupil, Florence Brunet-Possenti, Julie De Quatrebarbes, Jean-Jacques Grob, Philippe Saiag, Eve Maubec, Pierre-Emmanuel Stoebner, Florence Granel-Brocard, Jean-Philippe Arnault, Clara Allayous, Bastien Oriano, Céleste Lebbe & Henri Montaudié. (2022) Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort. Journal of the American Academy of Dermatology.
Crossref
Crossref
Biao Huang, Wenxing Su & Daojiang Yu. (2022) Data-driven analysis to identify prognostic immune-related biomarkers in BRAF mutated cutaneous melanoma microenvironment. Frontiers in Genetics 13.
Crossref
Crossref
Marta Morante, Atanasio Pandiella, Piero Crespo & Ana Herrero. (2022) Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. Biomolecules 12:11, pages 1562.
Crossref
Crossref
Yiqun Zhang, Shijie Lan & Di Wu. (2022) Advanced Acral Melanoma Therapies: Current Status and Future Directions. Current Treatment Options in Oncology 23:10, pages 1405-1427.
Crossref
Crossref
Elisa A. Rozeman, Judith M. Versluis, Ruben Moritz, Sofie Wilgenhof, Johannes V. van Thienen, John B.A.G. Haanen, Michel M. van de Heuvel, Christian U. Blank & Huub H. van Rossum. (2022) Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Clinica Chimica Acta 533, pages 71-78.
Crossref
Crossref
Hussein A Tawbi, Caroline Robert, Jan C Brase, Daniel Gusenleitner, Eduard Gasal, James Garrett, Alexander Savchenko, Güllü Görgün, Keith T Flaherty, Antoni Ribas, Reinhard Dummer, Dirk Schadendorf, Georgina V Long, Paul D Nathan & Paolo A Ascierto. (2022)
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with
BRAF
V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
. Journal for ImmunoTherapy of Cancer 10:6, pages e004226.
Crossref
Crossref
C. Robert, K.D. Lewis, R. Gutzmer, D. Stroyakovskiy, H. Gogas, S. Protsenko, R.P. Pereira, T. Eigentler, P. Rutkowski, L. Demidov, I. Caro, H. Forbes, K. Shah, Y. Yan, H. Li, G.A. McArthur & P.A. Ascierto. (2022) Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma. Annals of Oncology 33:5, pages 544-555.
Crossref
Crossref
Paolo A. Ascierto, Michael B. Atkins, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman & Igor Puzanov. (2021) The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020. Journal of Translational Medicine 19:1.
Crossref
Crossref
Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, Diana Giannarelli, Antonio M. Grimaldi, Domenico Mallardo, Gabriele Madonna, Marcello Curvietto, Assunta Esposito, Fabio Sandomenico, Francesco Sabbatino, Nicholas L. Bayless, Sarah Warren, SuFey Ong, Gerardo Botti, Keith T. Flaherty, Soldano Ferrone & Paolo A. Ascierto. (2021) A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine 19:1.
Crossref
Crossref
Eleonora Farinazzo, Enrico Zelin, Marina Agozzino, Giovanni Papa, Maria Antonietta Pizzichetta, Nicola di Meo & Iris Zalaudek. (2021) Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma. Melanoma Research 31:6, pages 582-585.
Crossref
Crossref
C.L. Gerard, J. Delyon, A. Wicky, K. Homicsko, Michel A. Cuendet & O. Michielin. (2021) Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews 101, pages 102227.
Crossref
Crossref
Danielle Verver, Dirk J. Grünhagen, Alexander C. J. van Akkooi, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Marye J. Boers-Sonderen, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Albert J.ten Tije, Gerard Vreugdenhil, Cornelis Verhoef & Astrid A. M. van der Veldt. (2021) Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. Cancer Immunology, Immunotherapy 70:11, pages 3123-3135.
Crossref
Crossref
Thomas Jung, Maximilian Haist, Michael Kuske, Stephan Grabbe & Matthias Bros. (2021) Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond. International Journal of Molecular Sciences 22:18, pages 9890.
Crossref
Crossref
Federica Giugliano, Edoardo Crimini, Paolo Tarantino, Paola Zagami, Jacopo Uliano, Chiara Corti, Dario Trapani, Giuseppe Curigliano & Paolo A. Ascierto. (2021) First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews 99, pages 102253.
Crossref
Crossref
Henner Stege, Maximilian Haist, Michael Schultheis, Maria Isabel Fleischer, Peter Mohr, Friedegund Meier, Dirk Schadendorf, Selma Ugurel, Elisabeth Livingstone, Lisa Zimmer, Rudolf Herbst, Claudia Pföhler, Katharina Kähler, Michael Weichenthal, Patrick Terheyden, Dorothée Nashan, Dirk Debus, Martin Kaatz, Fabian Ziller, Sebastian Haferkamp, Andrea Forschner, Ulrike Leiter, Alexander Kreuter, Jens Ulrich, Johannes Kleemann, Fabienne Bradfisch, Stephan Grabbe & Carmen Loquai. (2021) Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study. Cancers 13:10, pages 2312.
Crossref
Crossref
Carolina Mendonça Gorgulho, Anuradha Krishnamurthy, Anastasia Lanzi, Jérôme Galon, Franck Housseau, Ramon Kaneno & Michael T. Lotze. (2021) Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. Journal of Immunotherapy 44:2, pages 49-62.
Crossref
Crossref
Yuanxin Miao, Zhenyu Chen, Zhiguo Wang, Chunnan Hu, Lu Chen & Hao Sun. (2021) Hemidesmus indicus (l)-derived 2-hydroxy-4-methoxy benzoic acid attenuates dna damage and autophagy in sk-mel28 cells via p-erk pathway. Pharmacognosy Magazine 17:76, pages 819.
Crossref
Crossref
A. M. Di Giacomo, Elisabetta Gambale & Michele Maio. 2021. New Therapies in Advanced Cutaneous Malignancies. New Therapies in Advanced Cutaneous Malignancies
281
310
.
S. A. Protsenko, E. N. Imyanitov, A. I. Semenova, D. Kh. Latipova, A. V. Novik, D. O. Yurlov & A. P. Oganesian. (2020) Modern combined targeted and immunotherapy of metastatic skin melanoma. Meditsinskiy sovet = Medical Council:20, pages 54-61.
Crossref
Crossref
Andrea Boutros, Chiara Schiavi, Federica Cecchi, Francesco Spagnolo, Antonio Guadagno, Enrica Teresa Tanda, Francesca Giusti, Giuseppe Murdaca & Paola Queirolo. (2020) Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient. Frontiers in Immunology 11.
Crossref
Crossref
Olivier Michielin, Michael B Atkins, Henry B Koon, Reinhard Dummer & Paolo Antonio Ascierto. (2020) Evolving impact of long-term survival results on metastatic melanoma treatment. Journal for ImmunoTherapy of Cancer 8:2, pages e000948.
Crossref
Crossref
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, Mario Mandalà, Paul D. Nathan, Ana Arance, Erika Richtig, Naoya Yamazaki, Caroline Robert, Dirk Schadendorf, Hussein A. Tawbi, Paolo A. Ascierto, Antoni Ribas, Keith T. Flaherty, Neha Pakhle, Catarina D. Campbell, Daniel Gusenleitner, Aisha Masood, Jan C. Brase, Eduard Gasal & Georgina V. Long. (2020) Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine 26:10, pages 1557-1563.
Crossref
Crossref
G. Curigliano, S. Banerjee, A. Cervantes, M.C. Garassino, P. Garrido, N. Girard, J. Haanen, K. Jordan, F. Lordick, J.P. Machiels, O. Michielin, S. Peters, J. Tabernero, J.Y. Douillard, G. Pentheroudakis, A. Addeo, L. Albiges, P.A. Ascierto, S. Banerjee, F. Barlesi, C. Caldas, F. Cardoso, A. Cervantes, I.F. Chaberny, N.I. Cherny, T.K. Choueiri, M.L.K. Chua, C. Criscitiello, G. Curigliano, E. de Azambuja, D. De Ruysscher, E. de Vries, R. Dent, J.Y. Douillard, D. D’Ugo, R. Dziadziuszko, C. Faivre-Finn, E. Felip, M. Garassino, P. Garrido, N. Girard, R. Glynne-Jones, V. Golfinopoulos, J. Haanen, E. Hamilton, P.A. Jänne, K. Jordan, R. Kanesvaran, S.B. Kim, U.G. Liebert, F. Lordick, J.P. Machiels, O. Michielin, T.S.K. Mok, G. Morgan, R. Obermannova, K. Park, A. Passaro, G. Pentheroudakis, S. Peters, M. Reck, R. Salazar Soler, F. Scotté, S. Senan, C. Sessa, E. Smyth, R. Soo, J.C. Soria, J. Spicer, F. Strasser, J. Tabernero, D.S.W. Tan, D. Trapani, E. Van Cutsem, H. van Halteren, P.E. van Schil, G. Veronesi & J. Yang. (2020) Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Annals of Oncology 31:10, pages 1320-1335.
Crossref
Crossref
Christoph Hoeller. (2020) The future of combination therapies in advanced melanoma. memo - Magazine of European Medical Oncology 13:3, pages 309-313.
Crossref
Crossref
Eva Crespo-Rodriguez, Katharina Bergerhoff, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Harriet Whittock, Richard Buus, Syed Haider, Gareth Muirhead, Khin Thway, Kate Newbold, Robert S Coffin, Richard G Vile, Dae Kim, Martin McLaughlin, Alan A Melcher, Kevin J Harrington & Malin Pedersen. (2020) Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Journal for ImmunoTherapy of Cancer 8:2, pages e000698.
Crossref
Crossref
A. Zaremba, L. Zimmer, K. G. Griewank, S. Ugurel, A. Roesch, D. Schadendorf & E. Livingstone. (2020) Malignes MelanomMalignant melanoma. Der Onkologe 26:8, pages 713-720.
Crossref
Crossref
Anna M. Czarnecka, Ewa Bartnik, Michał Fiedorowicz & Piotr Rutkowski. (2020) Targeted Therapy in Melanoma and Mechanisms of Resistance. International Journal of Molecular Sciences 21:13, pages 4576.
Crossref
Crossref
Magdalena Olbryt, Marcin Rajczykowski & Wiesława Widłak. (2020) Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 21:11, pages 4071.
Crossref
Crossref
Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy Moiseevich Manikhas, Yibing Yan, Kuan-Chieh Huang, Anne Uyei, Virginia McNally, Grant A McArthur & Paolo A Ascierto. (2020) Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 395:10240, pages 1835-1844.
Crossref
Crossref
Rosa Noguera, Rebeca Burgos-Panadero, Federico Lucantoni, Luis de la Cruz-Merino & Tomás Álvaro Naranjo. (2020) Una visión integral del cáncer (III). Evaluación de nuevos biomarcadores y posibilidades de intervención. Revista Española de Patología 53:2, pages 88-99.
Crossref
Crossref
Reinhard Dummer, Jan C Brase, James Garrett, Catarina D Campbell, Eduard Gasal, Matthew Squires, Daniel Gusenleitner, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, Keith Flaherty, James Larkin, Caroline Robert, Richard Kefford, John M Kirkwood, Axel Hauschild, Dirk Schadendorf & Georgina V Long. (2020) Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The Lancet Oncology 21:3, pages 358-372.
Crossref
Crossref
Hima Patel, Nour Yacoub, Rosalin Mishra, Aaron White, Long Yuan, Samar Alanazi & Joan T. Garrett. (2020) Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers 12:2, pages 482.
Crossref
Crossref
Soudabeh Rad Pour, Hiromasa Morikawa, Narsis A. Kiani, David Gomez-Cabrero, Alistair Hayes, Xiaozhong Zheng, Maria Pernemalm, Janne Lehtiö, Damian J. Mole, Johan Hansson, Hanna Eriksson & Jesper Tegnér. (2020) Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma. Frontiers in Oncology 10.
Crossref
Crossref
Keiran S.M. Smalley. (2020) Two Worlds Collide: Unraveling the Role of the Immune System in BRAF–MEK Inhibitor Responses. Cancer Discovery 10:2, pages 176-178.
Crossref
Crossref
Helen K. Angell, Daniela Bruni, J. Carl Barrett, Ronald Herbst & Jérôme Galon. (2020) The Immunoscore: Colon Cancer and Beyond. Clinical Cancer Research 26:2, pages 332-339.
Crossref
Crossref
D Verver, AAM van der Veldt, ACJ van Akkooi, C Verhoef, DJ Grünhagen & WJ Louwman. (2019) Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study. International Journal of Cancer 146:1, pages 26-34.
Crossref
Crossref
Paolo Antonio Ascierto, Lorenzo Borgognoni, Gerardo Botti, Michele Guida, Paolo Marchetti, Simone Mocellin, Paolo Muto, Giuseppe Palmieri, Roberto Patuzzo, Pietro Quaglino, Ignazio Stanganelli & Corrado Caracò. (2019) New paradigm for stage III melanoma: from surgery to adjuvant treatment. Journal of Translational Medicine 17:1.
Crossref
Crossref
Maria Rosaria Ruocco, Angelica Avagliano, Giuseppina Granato, Elena Vigliar, Stefania Masone, Stefania Montagnani & Alessandro Arcucci. (2019) Metabolic flexibility in melanoma: A potential therapeutic target. Seminars in Cancer Biology 59, pages 187-207.
Crossref
Crossref
Michele Guida, Nicola Bartolomeo, Ivana De Risi, Livia Fucci, Andrea Armenio, Ruggero Filannino, Eustachio Ruggieri, Francesco Macina, Michele Traversa, Annalisa Nardone, Francesco Figliuolo, Federica De Luca, Fabio Mele, Stefania Tommasi & Sabino Strippoli. (2019) The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma. Cancers 11:10, pages 1559.
Crossref
Crossref
Qingliang Yu, Jiayi Xie, Jiangmiao Li, Yunxin Lu & Liang Liao. (2019) Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review. Cancer Medicine 8:12, pages 5414-5424.
Crossref
Crossref
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar-Sela, Felix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno & Antoni Ribas. (2019) Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine 25:6, pages 941-946.
Crossref
Crossref
Francesca Consoli, Ausilia Maria Manganoni, Salvatore Grisanti, Fausto Petrelli, Marina Venturini, Giovanni Rangoni, Francesco Guarneri, Paolo Incardona, William Vermi, Pier Giacomo Calzavara Pinton & Alfredo Berruti. (2019) Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy. PLOS ONE 14:4, pages e0214884.
Crossref
Crossref